EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches

Journal of Experimental & Clinical Cancer Research

M. Caraglia³  F. Casale¹  P. Indolfi¹  M. Di Martino¹  G. Pecoraro¹  M. C. Affinita¹  V. Desiderio²  M. R. Zarone³  A. Lombardi³  M. Ramaglia¹  A. Iannotta¹  V. D’Angelo¹ 

[1] Department of Woman, Child and General and Specialized Surgery, Pediatric Oncology Unit - Second University of Naples, Via Luigi De Crecchio 4, Naples, 80138, Italy;Department of Experimental Medicine, Section of Biotechnology and Medical Histology and Embryology, Second University of Naples, Naples, Italy;Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Via S.M. Costantinopoli, 16, Naples, 80138, Italy

关键词: T-cell Acute Lymphoblastic Leukemia;    DZNep;    EZH2;   

Others  :  1225512
DOI  :  10.1186/s13046-015-0191-0

 received in 2015-05-28, accepted in 2015-07-17,  发布年份 2015

【 摘 要 】

Background

T-cell Acute Lymphoblastic Leukemia (ALL) represents about 10–15 % of pediatric ALL cases. EZH2, one of the components of Polycomb group proteins (PRC2) complex, catalyzes the trimethylation of histone H3 lysine 27 that is associated with transcriptional repression and tumor development.

Methods

We examined the expression levels of PRC2 complex in primary samples of T cells ALL at diagnosis by western blotting and real time PCR. We evaluated the effect of 3-deazaneplanocin-A (DZNep), an EZH2 inhibitor, alone and in combination with Daunoblastine on cell viability, apoptotic death and cell cycle distribution of T cell established Jurkat cell line.

Results

EZH2 was expressed in 75 % samples at different extents mainly with high expression level. SUZ12 was expressed in 60 % samples and EED in all samples, respectively. The Kaplan-Meier analysis shows that T-ALL expressing EZH2 had a lower probability of disease-free survival (DFS) compared to T-ALL negative for EZH2 (23 % vs 100 %) (p = 0.01). The EZH2 inhibitor DZNep used in combination with Daunoblastine was synergistic in inducing growth inhibition and increasing the apoptosis in T-ALL Jurkat cells at 48 and 72 h paralleled by EZH2 decreased expression. Moreover, the combination decreased the activity of Erk-1/2 proliferation enzymes with no effects on Akt survival pathway.

Conclusions

The evaluation of EZH2 expression in pediatric T-ALL can be useful in predict the clinical outcome of the patients and EZH2 can be a useful target to improve the efficacy of conventional chemotherapy in this subset of patients with bad prognosis.

【 授权许可】

   
2015 D’Angelo et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

Fig. 7.

Fig. 8.

【 参考文献 】

• [1]Xie H, Xu J, Hsu Jessie H, Nguyen M, Fujiwara Y, Peng C, Orkin SH: Polycomb Repressive Complex 2 Regulates Normal Hematopoietic Stem Cell Function in a Developmental-Stage-Specific Manner. Cell Stem Cell. 2014, 14:68-80.
• [2]Momparler LR, Idaghdour Y, Marquez EV, Momparler FL: Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation. Leukemia Research 2012, 36:1049-1054.
• [3]Chase A, Cross NC: Aberrations of EZH2 in cancer. Cancer Res 2011, 9(17):2613-8.
• [4]Lund K, Adams PD, Copland M: EZH2 in normal and malignant hematopoiesis. Leukemia. 2014, 28:44-49.
• [5]Astolfi A, Vendemini F, Urbini M, Melchionda F, Masetti R, Franzoni M, Libri V, Serravalle S, Togni M, Paone G, Montemurro L, Bressanin D, Chiarini F, Martelli AM, Tonelli R, Pession A: MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia. Oncotarget. 2013, 5:1.
• [6]Girard N, Bazille C, Lhuissier E, Benateau H, Llombart-Bosch A, Boumediene K, Bauge C: 3-Deazaneplanocin A (DZNep), an Inhibitor of the Histone Methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cells. PLOS One 2014, 9:5.
• [7]Sarma K, Margueron R, Ivanov A, Pirrotta V, Reinberg D: Ezh2 requires PHF1 to efficiently catalyze H3 lysine 27 trimethylation in vivo. Mol Cell Biol. 2008, 28:2718-31.
• [8]Zhou J, Bi C, Cheong LP, Mahara S, Liu SC, Koh T, Yu Q, Chng WJ: The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood. 2011, 18:10.
• [9]Fiskus W, Rao R, Balusu R, Ganguly S, Tao J, Sotomayor E, Mudunuru U, Smith JE, Hembruff SL, Atadja P, Marquez VE, Bhalla K: Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells. Clin Cancer Res 2012, 18:6227-6238.
• [10]Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, Ustun C, Rao R, Fernandez P, Chen J, Balusu R, Koul S, Atadja P, Marquez VE, Bhalla KN: Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3- deazaneplaocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009, 114:2733-2743.
• [11]Puppe J, Drost R, Liu X, Joosse SA, Evers B, Cornelissen-Steijger P, Nederlof P, Yu Q, Jonkers J, van Lohuizen M, Pietersen AM: BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res 2009, 11:R63. BioMed Central Full Text
• [12]Crea F, Hurt EM, Mathews LA, Cabarcas SM, Sun L, Marquez VE, Danesi R, Farrar WL: Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol Cancer. 2011, 10:40. BioMed Central Full Text
• [13]Hayden A, Johnson PW, Packham G, Crabb SJ: S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition. Breast Cancer Res Treat. 2011, 127:109-19.
• [14]Kikuchi J, Takashina T, Kinoshita I, Kikuchi E, Shimizu Y, Sakakibara-Konishi J, et al.: Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer. 2012, 78:138-43.
• [15]Zhaomei M, Hua L, Fernandez SV, Alpaugh KR, Zhang R, Cristofanilli M: EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells. J Exp Clin Cancer Res 2013, 32:70. BioMed Central Full Text
• [16]Jiang X, Tan J, Li J, Kivimae S, Yang X, Zhuang L, et al.: DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell. 2008, 13:529-41.
• [17]Tacar O, Sriamornsak P, Dassa CR: Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. Journal of Pharmacy and Pharmacology 2013, 65:157-170.
• [18]Ilisso CP, Castellano M, Zappavigna S, Lombardi A, Vitale G, Dicitore A, et al. The methyl donor S-adenosylmethionine potentiates doxorubicin effects on apoptosis of hormone-dependent breast cancer cell lines. Endocrine. 2015;11.
• [19]Rossi M, Rotblat B, Ansell K, Amelio I, Caraglia M, Misso G, Bernassola F, Cavasotto CN, Knight RA, Ciechanover A, Melino G: High throughput screening for inhibitors of the HECT ubiquitin E3 ligase ITCH identifies antidepressant drugs as regulators of autophagy. Cell Death Dis 2014, 1:5:e1203.
• [20]Amodio N, Di Martino MT, Foresta U, Leone E, Lionetti M, Leotta M, Gullà AM, Pitari MR, Conforti F, Rossi M, Agosti V, Fulciniti M, Misso G, Morabito F, Ferrarini M, Neri A, Caraglia M, Munshi NC, Anderson KC, Tagliaferri P, Tassone P: miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis 2012, 29:3:e436.
• [21]Schrappe M, Hunger SP, Pui CH, Saha V, Gaynon PS, Baruchel A, Conter V, Otten J, Ohara A, Versluys AB, Escherich G, Heyman M, Silverman LB, Horibe K, Mann G, Camitta BM, Harbott J, Riehm H, Richards S, Devidas M, Zimmermann M: Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med 2012, 12(366):1371-81.
• [22]Milani G, Rebora P, Accordi B, Galla L, Bresolin S, Cazzaniga G, Buldini B, Mura R, Ladogana S, Giraldi E, Conter V, Te Kronnie G, Valsecchi MG, Basso G: Low PKCα expression within the MRD-HR stratum defines a new subgroup of childhood T-ALL with very poor outcome. Oncotarget. 2014, 5:14.
• [23]Cousta- Smith E, Mullighan CG, Behm FG OM, Raimondi SC, Pei D, Cheng C, Su X, Rubnitz JE, Basso G, Biondi A, Pui CH, Downing JR, Campana D: Early T-cell precursor Leukemia: a subtype of very high risk acute lymphoblastic Leukemia. Lancet Oncol 2009, 10:147-156.
• [24]Pounds SB, Ulyanov A, Becksfort J, Gupta P, Huether R, Kriwacki RW, Parker M, McGoldrick DJ, Zhao D, Alford D, Espy S, Bobba KC, Song G, Pei D, Cheng C, Roberts S, et al.: The genetic basis of early T-cell precursor acute lymphoblastic leukemia. Nature 2012, 481:157-163.
• [25]Wang C, Liu Z, Woo CW, Li Z, Wang L, We JS, Marquez VE, Bates SE, Jin Q, Khan J, Ge K, Thiele CJ: EZH2 mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3 and NGFR. Cancer Research 2011.
• [26]Ciarapica R, Miele L, Giordano A, Locatelli F, Rota R: Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications. BMC Medicine. 2011, 9:63. BioMed Central Full Text
• [27]Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET, Yu Q: Pharmacological disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007, 21:1050-10639.
• [28]Miranda T, Cortez CC, Yoo CB, Liang G, Abe M, Kelly TK, Marquez VE, Jones PA: DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 2009, 8:1579-1588.
• [29]Liu X, Chen X, Yu X, Tao Y, Bode AM, Dong Z, Cao Y: Regulation of microRNAs by epigenetics and their interplay involved in cancer. J Experim Clin Cancer Res 2013, 32:96. BioMed Central Full Text